Reparixin racemate is primarily used as an inhibitor of CXCR1 and CXCR2 chemokine receptors, which play key roles in inflammatory processes. It is investigated for its potential to reduce tissue damage caused by inflammatory responses, particularly in conditions involving neutrophil activation and infiltration. One major application is in transplant medicine, where it has been studied to prevent ischemia-reperfusion injury in organ transplants, such as pancreatic islet transplantation for type 1 diabetes. By blocking the recruitment of immune cells to the transplant site, reparixin helps improve graft survival and function. It has also shown promise in preclinical models of inflammatory diseases, including lung injury, arthritis, and certain cancers, due to its ability to modulate tumor microenvironment and inhibit cancer stem cell activity. Its use remains largely in research and clinical trial settings, focusing on immunomodulation with minimal broad immunosuppressive effects.